Chronic Myloid Leukaemia (CML) is a myeloproliferative neoplasm that originates in an abnormal pluripotent stem cell. Imatinib, a tyrosine kinase inhibitor, is the drug of choice for CML in the present time. During therapy, a few patients develop myelosuppression and present with cytopenias.